Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
NCT06932081
Adult Congenital Heart Disease, Cardiovascular Abnormalities
Baltimore, Maryland, United States
View Trial DetailsNCT Number: NCT06258083
Patients with the transposition of great arteries (TGA) who undergo atrial switch operation and congenitally corrected TGA (ccTGA) patients have the right ventricle as their systemic ventricle. Function of the systemic right ventricle (SRV) could deteriorate which is associated with impaired prognosis. It is of paramount importance to understand the course and fate of these patients during a long-term follow-up to identify the determinants of adverse outcomes.
Looking for future studies?
Notify Me12 year and older
All sexes
Observational
Universitair Ziekenhuis Leuven, Leuven, Belgium
In the year 2000, the prevalence of congenital heart diseases (CHD) patients with transposition of great arteries (TGA) was 0.027% in living children and 0.004% in living adults (1). Considering a complete transition to arterial switch operation in the 1990s, it is expected that the number of patients with systemic right ventricle (SRV) decrease over time (2). However, considering the existing number of patients with the TGA who have not undergone arterial switch surgery, SRV remains a challenging issue in the practice of adult congenital heart disease (ACHD) specialists.
TGA is characterized by AV concordance and ventriculo-arterial discordance and is called simple without the presence of associated congenital anomalies. However, complex TGA is when other anomalies are present including VSD (∼45%), LVOTO (∼25%), and CoA (∼5%). TGA's pathogenesis is controversial and there is rare familial occurrence. Male are two times more affected than females. The prognosis of TGA patients without surgery is poor and only exceptional cases survive to adulthood (3).
Heart failure and sudden cardiac death (SCD) are the predominant causes of mortality in TGA patients (4). Patients who undergo atrial switch operation and congenitally corrected TGA (ccTGA) patients are at risk of developing SRV failure in the future (3). The RV is a thin-walled triangular structure acting as a low pressure pump in the normal heart. Because of having only 2 layers, the RV cannot cause the torsion caused by the LV. Due to this geometry and anatomy, the right ventricular function is highly dependent on the loading conditions. The increased afterload that the RV faces in the systemic position causes compensatory RV dilation to maintain the stroke volume. Subsequently, there is increased myocardial wall stress and oxygen demand. The development of heart failure in the SRV is multifactorial. Other potential factors contributing to the SRV failure are impaired coronary reserve or ischemia, myocardial fibrosis, chronotropic incompetence, volume overload from tricuspid regurgitation and arrhythmias (4). Another contributing factor is the reduced baffle compliance in patients with atrial switch. This impairs the preload and stroke volume, especially when there is increased demand. The non-contractile atrial baffles cause impaired atrioventricular transport during tachycardia, therefore causing an inadequate RV filling (4).
Unfortunately, at the moment, the hypothesis that angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), aldosterone antagonists, and beta-blockers can improve the outcome of such patients alone or in combination is not supported by data and evidence. There is no solid recommendation in the 2020 guidelines for the management of ACHD (3).
Previous studies evaluating the fate and outcome of patients with an SRV are either mostly single-centered with a small number of patients or have a short follow-up period (5,6). In a study done by Richard Dobson and colleagues on a national cohort in Scotland, the investigators concluded that patients with an SRV who survive to adulthood have low mortality and good functional status up to the age of 40 (7).
It is of paramount importance to understand the course and fate of these patients during a long-term follow-up to identify the determinants of adverse outcomes. This will enable the investigators to investigate mechanistic pathways of such outcomes. By understanding the risk factors and pathophysiological basis, the investigators can also investigate new diagnostic methods and therapeutic options to improve the quality of life and reduce the mortality of patients with an SRV.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion, an average of 18 years
Death
Time frame: Through study completion, an average of 18 years
Initiation or increase in dosage (if previously prescribed for another cause, i.e. hypertension) of loop diuretic, ACE-inhibitor/ARB therapy, or evidence-based beta blocker therapy because of new heart failure signs and symptoms (shortness of breath, fatigue, reduced exercise tolerance) AND AT LEAST 1 OF THE FOLLOWING: • BNP ≥400 pg/mL OR the following NT-proBNP levels according to age: < 50 years, ≥450 ng/L; 50-75 years, ≥900 ng/L; >75 years, ≥1800 ng/L OR systolic dysfunction (Systemic ventricle EF <50%) OR • BNP 100-400 pg/mL (or NT-proBNP levels below the thresholds according to age given above) AND structural or functional heart disease
Time frame: Through study completion, an average of 18 years
Rehospitalization, emergency ward visit, 24h observation stay AND Treatment with or increase in dosage if previously prescribed for another cause (i.e.hypertension) of loop diuretics or treatment with IV vasoactive agents.
Time frame: Through study completion, an average of 18 years
Events that cause emergency ward visit or hospitalization.
Time frame: Through study completion, an average of 18 years
Cerebrovascular events including any of (Hemorrhagic or ischemic): 1, TIA (symptoms less than 24 hours) 2, CVA (symptoms more than 24 hours) and also pulmonary embolism.
Time frame: Through study completion, an average of 18 years
Definitie Infective Endocarditis
Time frame: Through study completion, an average of 18 years
Tricuspid valve surgery
Time frame: Through study completion, an average of 18 years
Implantation of ventricular assist device
Time frame: Through study completion, an average of 18 years
Heart transplantation
Time frame: Through study completion, an average of 18 years
Aortic root more than 40 mm or aneurysm in other parts of aorta. Aortic dissection.
Time frame: Through study completion, an average of 18 years
Mean PAP of more than 25mmHg or systolic PAP of more than 40 mmHg.
Time frame: Through study completion, an average of 18 years
Surgical or angiographic reintervention of baffles in patients with surgically corrected transposition of the great arteries (due to stenosis or leakage).
Time frame: Through study completion, an average of 18 years
Due to ischemia. Angiographic or surgical intervention.
Time frame: Through study completion, an average of 18 years
Including pacmakers, ICDs and CRTs.
Time frame: At two time points. 1: Baseline 2. Through study completion, an average of 18 years
Evaluated by cardiopulmonary exercise test results.
Time frame: At two time points. 1: Baseline 2. Through study completion, an average of 18 years
Measured by echocardiography qualitatively
Time frame: At two time points. 1: Baseline 2. Through study completion, an average of 18 years
Measured by echocardiography qualitatively
University Medical Center Groningen
Other
Systemic Right Ventricle Long-term Outcome: a Multicentre Study
Acronym: SINCERE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06932081
Adult Congenital Heart Disease, Cardiovascular Abnormalities
Baltimore, Maryland, United States
View Trial DetailsNCT02161471
Aortic Coarctation, Cardiovascular Abnormalities
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT04452188
Aortopulmonary Septal Defect, Cardiopulmonary Bypass
Ann Arbor, Michigan, United States
View Trial DetailsNCT03469843
Cardiovascular Abnormalities, Cardiovascular Diseases
Barcelona, Spain
View Trial Details